[144] Humacyte, Inc. SEC Filing

Rhea-AI Filing Summary

Humacyte, Inc. (HUMA) Form 144 reports a proposed sale of 591,685 common shares valued at $936,653.92 to be sold approximately on 08/20/2025 through UBS Financial Services on NASDAQ. The filer states the shares were originally acquired on 08/26/2021 as an early-stage investor position converted to Humacyte shares upon the company’s SPAC transaction; the original block purchased was 18,930,004 shares and payment was in cash. The filing also discloses recent dispositions by AYABUDGE LLC of 549,360 shares on 08/18/2025 (gross proceeds $997,429) and 1,100,000 shares on 08/19/2025 (gross proceeds $1,790,244). The filer certifies no undisclosed material adverse information.

Positive

• Origin of shares disclosed: Acquisition date and conversion from SPAC are explicitly stated, clarifying provenance.
• Broker named: UBS Financial Services is identified, indicating use of an established broker for the sale.
• Filer attestation: Signature representation that no material nonpublic information is known provides standard compliance assurance.

Negative

• Recent substantial sales: AYABUDGE LLC sold a total of 1,649,360 shares over two days (08/18–08/19/2025), which could exert selling pressure in the short term.
• Relationship to issuer not specified: The filing does not state whether the seller is an insider or affiliate, limiting transparency about potential governance implications.

Insights

Securities Analyst

TL;DR: Significant holder sales reported across mid-August with a further proposed sale; transaction sizes are modest relative to total outstanding shares.

The filing documents a proposed sale of 591,685 shares and recent sales totaling 1,649,360 shares over two days. Against the reported outstanding share count of 158,372,173, these transactions represent a small fraction of the company’s float. The shares were acquired in 2021 via conversion from an early-stage investor position tied to the SPAC transaction, which clarifies the origin and long-held nature of the position. The use of UBS as broker is standard for block dispositions. Overall, this is a routine Rule 144 notice documenting secondary market sales rather than a new issuance or corporate action.

Corporate Governance Expert

TL;DR: Filing is a standard notification of proposed resale; signer affirms no undisclosed material information.

The Form 144 includes a required representation that the seller knows of no material nonpublic information, and it documents prior and proposed sales by AYABUDGE LLC. The filing does not state the filer’s formal relationship to the issuer, so governance implications are limited to disclosure of selling activity. Absent additional context about insider status or related-party relationships, this notice should be interpreted as a compliance disclosure under Rule 144 rather than a governance event signaling management change or regulatory concern.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	591685	936653.92	158372173	08/20/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	08/26/2021	EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC.	HUMACYTE INC			18930004	08/26/2021	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AYABUDGE LLC 95 ROSEMONT DRIVE DURHAM NC 27713	COMMON	08/18/2025	549360	997429
AYABUDGE LLC 95 ROSEMONT DRIVE DURHAM NC 27713	COMMON	08/19/2025	1100000	1790244

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the HUMA Form 144 propose to sell?

The notice proposes sale of 591,685 common shares with an aggregate market value of $936,653.92, to be sold around 08/20/2025 on NASDAQ via UBS Financial Services.

When and how were the shares originally acquired?

The shares were acquired on 08/26/2021 as an early-stage investment converted to Humacyte shares when the company went public via a SPAC; original block size shown is 18,930,004 shares and payment was in cash.

Has the seller already sold shares recently?

Yes. AYABUDGE LLC sold 549,360 shares on 08/18/2025 for $997,429 and 1,100,000 shares on 08/19/2025 for $1,790,244.

Who is the broker handling the proposed sale?

The broker named in the filing is UBS Financial Services Inc, located in Weehawken, NJ.

Does the filing indicate any undisclosed material information?

The filer certifies by signature that they do not know of any material adverse information about the issuer that has not been publicly disclosed.